| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press.
CORRESPONDENCE |
Re: Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect
Affiliations of authors: Division of Cancer Epidemiology and Genetics (WHC, SSD), and Center for Cancer Research (WML), National Cancer Institute, Bethesda, MD
Correspondence to: Wong-Ho Chow, PhD, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 8100, Bethesda, MD 20892-7240 (e-mail: choww@mail.nih.gov).
| The first 10% of the full text of this article appears below. |
The trends in mortality rates according to tumor size for renal cell cancer (RCC) patients that were calculated by Hollingsworth et al. (1) are misleading because most RCC patients survive beyond the year that they are diagnosed. The prolonged survival means that the mortality rates for patients diagnosed during a confined period (19832002) should be low during the initial years and increase over time as
Response to this Correspondence
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 570-571.